Biocon’s wholly-owned subsidiary -- Biocon Pharma has received approval from the U.S Food and Drug Administration (USFDA) for its ANDA for Liraglutide Injection (gVictoza), 18 mg/3 mL (6 mg/mL), Single-Patient-Use Prefilled Pens. Liraglutide is indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise.
This follows the approval for Liraglutide injection (gSaxenda) that was received by the company on February 24, 2026, and will further strengthen the company's portfolio of vertically integrated, complex drug products.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
